Cetera Investment Advisers raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,290 shares of the company’s stock after acquiring an additional 161 shares during the quarter. Cetera Investment Advisers’ holdings in IDEXX Laboratories were worth $9,885,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Riverview Trust Co acquired a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new stake in IDEXX Laboratories in the first quarter worth $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth $28,000. Finally, nVerses Capital LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $49,000. Institutional investors and hedge funds own 87.84% of the company’s stock.
IDEXX Laboratories Trading Down 1.2 %
NASDAQ:IDXX opened at $477.67 on Friday. The company has a market cap of $39.45 billion, a P/E ratio of 46.24, a price-to-earnings-growth ratio of 4.32 and a beta of 1.33. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The business has a 50 day moving average price of $487.95 and a two-hundred day moving average price of $495.89. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33.
Wall Street Analyst Weigh In
Several research firms have weighed in on IDXX. Piper Sandler reduced their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $582.25.
Check Out Our Latest Analysis on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
- Five stocks we like better than IDEXX Laboratories
- The Risks of Owning Bonds
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- What is the NASDAQ Stock Exchange?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.